Regeneron Pharmaceuticals (REGN) Change in Receivables (2009 - 2026)

Regeneron Pharmaceuticals' Change in Receivables history runs 18 years deep, the most recent figure standing at -$1.2 million for Q1 2026.

• On a quarterly basis, Change in Receivables rose 99.82% year-over-year to -$1.2 million in Q1 2026; TTM through Mar 2026 was $158.5 million, a 53.79% decrease from a year earlier, with the FY2025 full-year figure at -$498.1 million, down 189.91% from the prior year.
• Change in Receivables fell to -$1.2 million in Q1 2026 per REGN's latest filing, from $51.2 million in the prior quarter.
• Across five years, Change in Receivables topped out at $494.1 million in Q2 2024 and bottomed at -$1.2 billion in Q1 2022.
• The 5-year median for Change in Receivables is $51.2 million (2025), against an average of -$18.5 million.
• Across the five-year window, Change in Receivables sank 2154.03% in 2022 and soared 18200.0% in 2024, its largest moves.
• Year by year, Change in Receivables stood at -$219.6 million in 2022, then soared by 137.66% to $82.7 million in 2023, then jumped by 42.44% to $117.8 million in 2024, then tumbled by 56.54% to $51.2 million in 2025, then plunged by 102.34% to -$1.2 million in 2026.
• Per Business Quant, the three latest REGN Change in Receivables figures stand at -$1.2 million (Q1 2026), $51.2 million (Q4 2025), and $80.3 million (Q3 2025).